Surrozen filings document a biotechnology issuer focused on Wnt signaling and antibody technologies for ophthalmic disease. Recent Form 8-K reports disclose operating results, financial condition, pipeline business updates for SZN-8141 and related retinal disease programs, and collaboration and license revenue tied to research milestones.
The company's regulatory reports also record governance and compensation matters, including board and executive changes and inducement equity arrangements, along with material-agreement disclosures such as the termination of the TCGFB collaboration for antibody discovery services. Cover-page data and exhibits identify Surrozen common stock and redeemable warrants as part of the public-company capital structure.
Surrozen, Inc. (SRZN) reported that TCGFB, Inc. elected to terminate their Collaboration Agreement. The notice was delivered on October 14, 2025, with termination effective November 13, 2025, and no termination penalties for either party.
Under the agreement, Surrozen provided antibody discovery services while TCGFB owned all TGF-β product intellectual property. In return, TCGFB agreed to pay Surrozen up to $6.0 million in the aggregate, plus third-party costs, and issued a warrant exercisable for up to 3.4 million TCGFB common shares at an exercise price of $0.0001 per share, subject to vesting conditions.
The arrangement was a related party transaction because entities affiliated with The Column Group hold more than 5% of Surrozen’s common stock and Dr. Kutzkey, a Surrozen director, serves as Managing Partner of The Column Group.